TrialSignal transduction and targeted therapy2024

Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.

Jie Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.